CORMEDIX Business Summary

CorMedix Inc. (CRMD) is a commercial-stage specialty pharmaceutical company that generates revenue through the direct sale of proprietary anti-infective therapies, primarily targeting the hospital acute care and outpatient hemodialysis markets. Its financial model is anchored by DefenCath, the first and only FDA-approved antimicrobial catheter lock solution (CLS) in the U.S. designed to prevent catheter-related bloodstream infections (CRBSIs). Following the strategic acquisition of Melinta Therapeutics in August 2025, the company diversified its revenue streams by adding a portfolio of seven established anti-infectives, including Vabomere, Minocin, and Rezzayo. CorMedix operates in a competitive landscape alongside global pharmaceutical giants such as Pfizer, Amphastar Pharmaceuticals, Baxter International, and Fresenius Kabi. While these competitors dominate the traditional heparin and anticoagulant markets, CorMedix maintains a distinct competitive advantage as a first-mover with a specialized, non-antibiotic antimicrobial solution that addresses a significant unmet need in infection prevention for chronic hemodialysis patients. The company is led by CEO and Chairman Joseph Todisco, who joined in 2022 and previously served as Chief Commercial Officer at Amneal Pharmaceuticals, where he co-founded Gemini Laboratories. The executive team was significantly bolstered in early 2026 with the appointment of Mike Seckler as EVP and Chief Commercial Officer, bringing extensive experience from Evome Medical Technologies and FerGene. Other key leaders include EVP and CFO Susan Blum, formerly the CFO of Melinta Therapeutics, and EVP and COO Liz Hurlburt, who oversees the integration of the Melinta portfolio. While CorMedix was originally incorporated in 2006, its current trajectory is shaped by a leadership team with deep pedigrees in specialty pharma and corporate development. The Board of Directors features notable industry veterans including Lead Independent Director Myron Kaplan, a founding partner of Kleinberg, Kaplan, Wolff & Cohen, and Robert Stewart, the CEO of Theramex and former CEO of Amneal. The company maintains a strong institutional investor base, with significant positions held by BlackRock and Vanguard.